Form 8-K BIOXYTRAN, INC For: Dec 02
- Wall St edges lower as Fed fears mount
- Dow Jones, Nasdaq, S&P 500 weekly preview: Stocks rally likely over - analysts
- Public Storage (PSA) makes an $11 billion unsolicited offer for Life Storage (LSI)
- Goldman reacts positively to Newmont's new $17 billion bid for Newcrest Mining
- Soft landing already priced in, S&P 500 upside limited from here - Goldman Sachs
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
of Report (Date of earliest event reported):
(Exact Name if Business Issuer as specified in its Charter)
or other Jurisdiction
(Address of principal executive offices, including zip code)
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)|
|Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))|
|Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Item 8.01 Other Events.
On December 2, 2022, Bioxytran (the “Company”) has through India’s Central Drugs Standard Control Organisation (CDSCO) received permission in form CT -06, No. CT/ND/ /2022, under the provisions of New Drugs and Clinical Trial Rules, 2019, to conduct: “A Phase 1b/2a Randomized, Blinded, placebo-controlled Study in Participants with Mild to Moderate COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Orally Administered ProLectin-M” with the registration F. No. IND/CT/22/000004.
A condition for the permission is that the clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority.
In connection of with the above approval the Company issued on December 8, 2022 a press-release over Newswire, under the title:
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
Item 9.01. Financial Statements and Exhibits.
|99.1||Press-release - Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients, dated December 8, 2022.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|By:||/s/ David Platt|
|Name:||Dr. David Platt|
|Title:||President and Chief Executive Officer|
Dated: December 8, 2022
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bioxytran Receives Approval to Initiate Trials with ProLectin-I
- Pitney Bowes Declares Common Stock Dividend
- RMA Appoints Guillaume Gau as Chief Operating Officer
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!